Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 138, Issue -, Pages 715-728Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2017.07.008
Keywords
Alzheimer's disease; Coumarin; Pargyline; Monoamine oxidases; A beta(1-42) aggregation
Categories
Funding
- Project of National Natural Sciences Foundation of China [81573313]
- Program for Changjiang Scholars and Innovative Research Team in University [PCSIRT-IRT_15R63]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
Ask authors/readers for more resources
A series of coumarin-pargyline hybrids (4a-x) have been designed, synthesized and evaluated as novel dual inhibitors of Alzheimer's disease (AD). Most of the compounds exhibited a potent ability to inhibit amyloid-beta (A(beta) aggregation and monoamine oxidases. In particular, compound 4x exhibited remarkable inhibitory activities against monoamine oxidases (IC50, 0.027 +/- 0.004 AM for MAO-B; 3.275 +/- 0.040 mu M for MAO-A) and A beta(1-42) aggregation (54.0 +/- 1.1%, 25 mu M). Moreover, compound 4x showed low toxicity according to in vitro cell toxicity test. The results of the parallel artificial membrane permeability assay for blood-brain barrier indicated that compound 4x would be potent to cross the blood-brain barrier. Collectively, these findings demonstrate that compound 4x was an effective and promising candidate for AD therapy. (C) 2017 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available